A: The most commonly
reported Sutent-related side
effects included diarrhea, skin
discoloration, mouth
irritation, weakness, and
altered taste.
Patients treated with Sutent
also experienced, fatigue, high
blood pressure, bleeding,
swelling, and taste
disturbance.
Hypothyroidism was also
observed.
Robert J. Motzer; et al. Sunitinib in Patients With
Metastatic Renal Cell Carcinoma. JAMA 2006
295: 2516-2524
reported Sutent-related side
effects included diarrhea, skin
discoloration, mouth
irritation, weakness, and
altered taste.
Patients treated with Sutent
also experienced, fatigue, high
blood pressure, bleeding,
swelling, and taste
disturbance.
Hypothyroidism was also
observed.
Robert J. Motzer; et al. Sunitinib in Patients With
Metastatic Renal Cell Carcinoma. JAMA 2006
295: 2516-2524
What is Sutent?
Sutent (sunitinib), is a targeted anti-cancer treatment for
patients with gastrointestinal stromal tumors (GIST), a rare
stomach cancer, and advanced kidney cancer.
Sutent (a tyrosine kinase inhibitor) was approved for the
treatment of patients with gastrointestinal stromal tumors
(GIST) whose disease has progressed or who are unable to
tolerate treatment with Gleevec(imatinib mesylate), the
current treatment for GIST patients.
FDA also granted accelerated approval for Sutent in the
treatment of patients with advanced renal cell carcinoma
(RCC).
In contrast to the approval for GIST, which was based on the
drug's ability to delay the growth of the tumors, this approval
was based on Sutent's ability to reduce the size of the tumors
in patients
Sunitinib “adds about six months of additional freedom from
progressing disease” to the two years that many patients
achieve from first-line treatment with imatinib" said Casali
during his presentation at the ASCO annual meeting.
"Sunitinib may work when imatinib is not effective because
sunitinib targets more than one cancer cell molecular
pathway and can block the action of several kinase
enzymes,” explains Barry Anderson, M.D., Ph.D., of the
National Cancer Institute’s Cancer Therapy Evaluation
Program.
“The work is exciting," he adds, "because we are learning
about the importance of particular cancer cell molecular
pathways and new strategies for striking at important
molecular targets may develop from such clinical trial data
that could extend such therapies to first-line treatment in
other types of cancers."
http://www.cancer.gov/clinicaltrials/results/sunitinib-and-GIST0806
Sutent (sunitinib), is a targeted anti-cancer treatment for
patients with gastrointestinal stromal tumors (GIST), a rare
stomach cancer, and advanced kidney cancer.
Sutent (a tyrosine kinase inhibitor) was approved for the
treatment of patients with gastrointestinal stromal tumors
(GIST) whose disease has progressed or who are unable to
tolerate treatment with Gleevec(imatinib mesylate), the
current treatment for GIST patients.
FDA also granted accelerated approval for Sutent in the
treatment of patients with advanced renal cell carcinoma
(RCC).
In contrast to the approval for GIST, which was based on the
drug's ability to delay the growth of the tumors, this approval
was based on Sutent's ability to reduce the size of the tumors
in patients
Sunitinib “adds about six months of additional freedom from
progressing disease” to the two years that many patients
achieve from first-line treatment with imatinib" said Casali
during his presentation at the ASCO annual meeting.
"Sunitinib may work when imatinib is not effective because
sunitinib targets more than one cancer cell molecular
pathway and can block the action of several kinase
enzymes,” explains Barry Anderson, M.D., Ph.D., of the
National Cancer Institute’s Cancer Therapy Evaluation
Program.
“The work is exciting," he adds, "because we are learning
about the importance of particular cancer cell molecular
pathways and new strategies for striking at important
molecular targets may develop from such clinical trial data
that could extend such therapies to first-line treatment in
other types of cancers."
http://www.cancer.gov/clinicaltrials/results/sunitinib-and-GIST0806
This publications contains the opinions and ideas of its author(s). It is intended to provide helpful and informative material
on the subjects addressed. It is written with the understanding that the author(s) is (are) not engaged in rendering
medical, health, or any other kind of professional service(s). The reader should consult his or her medical, health or other
competent professional before adopting any of the suggestions. The author(s) specifically disclaim all responsibility for
any liability, loss, or risk, personal or otherwise, which is incurred as a consequence, directly or indirectly, of the use and
application of any of the contents of this site.
on the subjects addressed. It is written with the understanding that the author(s) is (are) not engaged in rendering
medical, health, or any other kind of professional service(s). The reader should consult his or her medical, health or other
competent professional before adopting any of the suggestions. The author(s) specifically disclaim all responsibility for
any liability, loss, or risk, personal or otherwise, which is incurred as a consequence, directly or indirectly, of the use and
application of any of the contents of this site.